Activists — daily digest log

📅 Alpha Signal Digest — Jul 24, 2026 💰 INSIDER BUYS $FSBC · Five Star Bancorp (California commercial community bank): director cluster — Allbaugh ($4.25M, director+10% owner), Perry-Smith ($1.38M), Ramos ($250k), Deary-Bell ($250k) [CLUSTER of 4, ~$6.1M]. Why: buys landed alongside the company’s $113.6M common-stock offering priced at $44 — insiders backing the raise (supportive, but the offering is dilutive) · news. $ACOG · Alpha Cognition (CNS biotech; Alzheimer’s drug Zunveyl): Opaleye Management (10% owner, specialist healthcare fund) bought $1.57M. Why: continuation of steady open-market accumulation since early June — a dedicated biotech fund adding conviction into the Zunveyl launch · news. $PNFP · Pinnacle Financial Partners (Nashville-based regional bank): Robert McCabe Jr (chairman/founder) bought $1.0M. Why: open-market founder buy at ~$99.90 (not a 10b5-1 plan) — a confidence signal, though other insiders have been net sellers · news. $CLIR · ClearSign Technologies (industrial combustion / emissions-reduction tech): John Pasquesi via Otter Capital (10% owner) bought $1.77M. Why: the largest holder added through a $3.54 private placement — insider funding the balance sheet (capital injection, not open-market). $GDTC · CytoMed Therapeutics (Singapore cell-therapy / immuno-oncology biotech): Choo Chee Kong (director+10% owner) bought $300k. Why: insider adding to a micro-cap immuno-oncology name. Also (non-traded funds, not investable): a Blackstone affiliate bought ~$15M of Blackstone Private Real Estate Credit & Income Fund, Assured Guaranty added ~$5.2M to Sound Point Direct Lending BDC, and an AMG affiliate added ~$0.66M to AMG BBH Asset-Backed Credit Fund. 📊 Rest: 7 Schedule 13D filings today — all control / founder / SPAC-sponsor stakes (BOXABL founder Paolo Tiramani 94.8% & 86.5%, Nex Neo Tech 54.6%, Niki BioSolutions 51.6%, Karbon Capital SPAC sponsor 21.6%, T3 Defense 16.7%, Telos founder John Wood), not external activist accumulation. Research only — not investment advice.

📅 Activist & Insider Signals — July 24, 2026 (SEC filings dated Jul 23, 2026) 🔍 EMERGING (not on roster, stake ≥5%) $HSTC · HST Global, Inc. (homeopathic late-stage-cancer wellness centers) — 31.0% [Med] Michael L. Field (individual filer) — filed SCHEDULE 13D Why: An individual taking a controlling 31% position in a nano-cap OTC health shell — effectively a control filing, not an institutional activist play; near-zero liquidity is the main risk. $SNES · SenesTech, Inc. (rodent fertility-control / ContraPest maker) — 19.95% [Med] Glenbrook Capital Management (value-oriented investment manager) — filed SCHEDULE 13D Why: A long-time holder converting steady open-market accumulation into a 13D at ~20% — a value manager pressing a micro-cap pest-control story. Risk: SenesTech is a cash-burning nano-cap. · news $TMCR · The Metals Royalty Company Inc. (US critical-metals royalty & streaming) — 5.55% [Med] Michael Bernard Hess (individual filer) — filed SCHEDULE 13D Why: A fresh 13D on a recently Nasdaq-listed critical-minerals royalty vehicle riding the critical-minerals theme. Risk: pre-production, tiny float. 💰 INSIDER BUYS $COE · 51Talk Online Education Group (online English-tutoring platform): Jack Jiajia Huang (CEO, 10%+ owner) bought $10.5M [High]. Why: The CEO is continuing a months-long open-market buying campaign via HH Talent under a 10b5-1 plan — strong, persistent insider conviction. · news Commonwealth Credit Partners BDC I, Inc. (private, non-traded credit BDC): UAW Chrysler Retirees Medical Benefits Plan (10% owner) bought $9.9M [High]. Why: A large LP subscription into a non-traded BDC — structural capital deployment, not a tradable open-market signal. $BRTMU · B&R Technology Merger Corp. (blank-check SPAC): B&R Technology Sponsor LLC (10% owner) bought $6.9M [High]. Why: Sponsor buying placement/founder units at $10 — routine SPAC-sponsor mechanics, not an open-market conviction signal.

$ARTV · Artiva Biotherapeutics, Inc. (allogeneic NK-cell cancer/autoimmune therapies): RA Capital Management (director + 10% owner, ~$9B AUM) bought $2.58M [High]. Why: The top biotech crossover fund keeps adding after pushing its stake past 36%, with a partner on the board — high board-level conviction in Artiva's NK pipeline. Risk: clinical/binary. · news $ENR · Energizer Holdings, Inc. (batteries & auto-care products): Aqua Capital, Ltd. (10% owner) bought $2.43M [High]. Why: The 10% holder keeps buying into weakness — a persistent, no-sales accumulation in a leveraged consumer-staples name. · news $TSM · Taiwan Semiconductor (world's largest chip foundry): Tien Bor-Zen (VP) bought $301k [Med]. Why: A small, routine officer purchase — positive but not needle-moving for a mega-cap. $RBKB · Rhinebeck Bancorp, Inc. (NY community bank): Nancy Koskey Patzwahl (director) bought $299k [Med]. Why: A director open-market buy in a small-cap thrift — a modest insider-alignment signal. Research only — not investment advice.

🎯 Alpha Signal Digest — 22 Jul 2026 (0 Schedule 13D filings scanned; insider accumulation below) 💰 INSIDER BUYS $CLBK · Columbia Financial (NJ savings-bank holding co): 9 insiders — incl. COO Steven Klein, CEO Thomas Kemly, CFO Thomas Splaine — bought ~$4.3M combined [CLUSTER of 9]. Why: post-conversion insider cluster right after Columbia’s $1.7B second-step conversion and Northfield Bancorp merger closed (Jul 20) — a classic thrift-conversion confidence signal; risk is a rich ~39x P/E. · news $PBLS · Parabilis Medicines (clinical-stage biotech, IPO’d Jun 2026): RA Capital Management (director+10% owner) bought $6.92M [High]. Why: RA Capital (~$10B biotech crossover) adding above its $20 IPO price at $27–30, extending a 23.8% pre-IPO stake — high conviction in the pipeline continuing post-IPO; risk is binary clinical data and a 180-day lock-up. · news $HDSN · Hudson Technologies (refrigerant reclamation & sales): Hartree Partners (10% owner) bought $393K [Med]. Why: commodity house keeps accumulating the refrigerant-reclaim play into the HFC phase-down. · news $NMM · Navios Maritime Partners (diversified dry-bulk/tanker/container shipping): Angeliki Frangou (CEO+chair, 10% owner) bought $253K [Med]. Why: chair continues steady open-market unit buys — ongoing insider conviction in the shipper. · news Research only — not investment advice.

🗓 Activist & Insider Signals — 21 Jul 2026 1 Schedule 13D scanned · 6 qualifying open-market insider buys 💰 INSIDER BUYS $ENR · Energizer Holdings (batteries, auto care, portable lighting): Aqua Capital, Ltd. (10%-owner group) bought $2.02M [High]. Why: the Diez Ramirez family vehicle (~7.5M shares) has bought ENR repeatedly through July at $20.07–20.75, averaging up into a deleveraging story rather than trading around it. Catalyst: debt paydown plus battery/auto-care margin recovery; risk: still-levered balance sheet and soft discretionary demand. · news $CAG · Conagra Brands (packaged food — Birds Eye, Slim Jim, Healthy Choice): John P. Brase (President & CEO, director) bought 35,000 shares for $510,632 [Med]. Why: the highest-signal insider pattern on the tape today — a new CEO (took over 1 Jun) buying his first open-market stake right after halving the dividend and being dropped from the S&P 500, i.e. after the bad news was cleared. Catalyst: turnaround credibility into FY27 guidance; risk: multi-year fix, volume declines persist. · news $CV · CapsoVision (swallowable 360° capsule endoscopy for GI): Eliyahou Harari et al (10%-owner) bought $411k [Med]. Why: Harari (SanDisk co-founder) keeps adding to an already ~3.3M-share stake in a ~$6 microcap growing revenue ~15%; repeat anchor-holder buying post-IPO is the tell. Risk: tiny float, thin liquidity and continued cash burn. · news $GF · New Germany Fund (closed-end fund holding German mid-caps): Saba Capital Management (10%-owner) bought $259k [Med]. Why: Saba’s standard closed-end-fund playbook — accumulate a discounted fund, then push the board for a tender or open-ending. The trade is discount compression, not a view on German equities. Risk: slow-moving, board resistance, and NAV still tracks Europe. · news $PRQR · ProQR Therapeutics (Dutch RNA-editing biotech, Axiomer platform): Bart Filius (non-executive director) bought $258k [Med]. Why: a director adding again after his June purchase on a sub-$2 stock — insider conviction ahead of Axiomer data and potential partnership economics. Risk: clinical binary and financing overhang at this market cap. · news

$STWI · StageWise Strategies (OTC shell, ex-SEO services, ~$150k market cap): Jakhongir Artikkhodjaev (10%-owner) bought $250k [Med]. Why: not a conviction signal — he already controls 74.2% and simply subscribed for 1,000,000 new shares at $0.25. Read as recapitalisation of a shell ahead of a reverse-merger, not open-market accumulation. Risk: no liquidity, no operating business. · news 📊 Rest: +1 other 13D filing today — RA Capital’s sponsor stake of 17.0% in its own SPAC Research Alliance Corp IV (healthcare blank-check, $75M Nasdaq IPO on 13 Jul). Structural sponsor filing, not an activist campaign. Research only — not investment advice.

📅 20 Jul 2026 — Activist & Insider Digest (late catch-up: SEC published Monday's index after the morning run) 🔍 EMERGING (high-conviction, not on roster) $SGRP · SPAR Group, Inc. (retail merchandising and in-store services) — 31.4% [Med] ReposiTrak, Inc. (public food-traceability SaaS vendor, ~$700M mkt cap) Why: Not a conviction accumulation — ReposiTrak is SPAR's service provider taking equity in lieu of cash under an amended services agreement, which mechanically lifted it to ~31%. Read as vendor-financing of a distressed micro-cap, not an activist campaign; dilution is the main risk. · news $CMDB · Costamare Bulkers Holdings Ltd (dry-bulk shipowner and operator) — 20.5% [Med] Konstantakopoulos Achillefs (founding family principal, control holder) Why: Structural family-control disclosure following the May-2025 spin-off from Costamare (CMRE), where the family retained ~63% in aggregate. Signal value is low — this is governance continuity, not new money; the real driver remains dry-bulk rates. · news

💰 INSIDER BUYS $CBIO · Crescent Biopharma (antibody/ADC oncology developer): Fairmount Funds Management (director + 10%-owner) bought $12.4M. Why: Fairmount is the architect here — it founded Paragon, the antibody engine Crescent licenses from, and led the $200M syndicate that took Crescent public via the GlycoMimetics reverse merger. Adding at size is insider-adjacent conviction rather than an outside vote; risk is that it is also the seller of record on the underlying IP economics. · news $COE · 51Talk Online Education Group (online English tutoring, Philippines-focused): Huang Jack Jiajia (director + officer + 10%-owner) bought $8.5M. Why: The CEO has been buying relentlessly through his HH Talent vehicle all year — into a drawdown from ~$27 to the mid-teens. That is the most persistent insider bid on this list. Caveat: purchases run under a pre-set Rule 10b5-1 plan, so they are mechanical rather than a fresh discretionary signal. · news $ARTV · Artiva Biotherapeutics (allogeneic NK-cell cell therapy): RA Capital Management (biotech crossover specialist, ~$12.6B AUM) (director + 10%-owner) bought $1.4M. Why: A top-up, not a new position — RA already sits near 36% after ~$100M committed in the May offering, and has been buying steadily on the way down from $11.52 to ~$8.95. Averaging down at this ownership level signals they intend to fund the thesis through data; binary clinical risk is the obvious offset. · news

$ZSTK · ZeroStack Corp. (decentralized-AI treasury vehicle, ex-Flora Growth): Heinrich Michael (director + officer) bought $3.5M. Why: Heinrich (0G Labs founder, exec chairman since Sep-2025) putting $3.5M into an ~$8M-market-cap shell is enormous relative to size. Treat with care: this name recently settled a convertible note in tokens and re-branded from a cannabis company, so the reported buy may not be economically equivalent to open-market cash. · news $FULC · Fulcrum Therapeutics (small-molecule genetic-disease biotech): Tang Kevin (10%-owner) bought $595k. Why: Tang is a known cash-shell/liquidation-value operator who accumulates biotechs trading near or below net cash and pushes for return of capital. His presence usually flags a balance-sheet play rather than a pipeline bet. $FCEL · FuelCell Energy (stationary fuel-cell power platforms): Livingston III Homer John (director) bought $495k. Why: A sizeable open-market director buy in a chronically dilutive, cash-burning name — modest but genuine alignment. Watch as a sentiment marker into the next data-center/power-demand headline, not a balance-sheet fix. $LNBIX · Lincoln Bain Capital Total Credit Fund (interval fund, private credit): Lincoln Financial Investments Corp (10%-owner) bought $25.0M. Why: Largest dollar figure of the day but not an alpha signal — this is the adviser seeding its own newly launched interval fund at NAV. Flagged only so the size is not mistaken for conviction. · news 📊 Rest: +1 other 13D filing (Founder Group Ltd, 4.42%, below threshold). ⚠️ Note: no roster names and no High-conviction 13Ds today — all three 13Ds are control/structural filings rather than activist campaigns. The insider-buy layer is where today's signal sits. Research only — not investment advice.

🗓 Activist & Insider Signals — July 17, 2026 🔍 EMERGING (high-conviction, not on roster) $TACT · TransAct Technologies (casino & food-service printers / POS software) — 15.22% [Med] Poplar Point Capital Management (microcap value / special-situations fund, ~$104M AUM) Why: Concentrated longtime holder (run by ex-Farallon PM Jad Fakhry) lifting its stake in a cheap small-cap — catalyst is capital-return / strategic pressure; main risk is TACT's thin liquidity and lumpy hardware sales · news 💰 INSIDER BUYS $ELV · Elevance Health (major US health insurer): CEO Gail Boudreaux bought $1.0M and director Ramiro Peru bought $366K [CLUSTER of 2]. Why: two insiders buying into ELV's worst drawdown in 15 years (~10% weekly drop) — a confidence signal on 2026 guidance; risk is medical-cost inflation · news. John Hancock GA Mortgage Trust (affiliated mortgage trust): Manulife group entities (Bermuda, International, Reinsurance, Singapore) bought ~$78M combined [CLUSTER of 4]. Why: intra-group structural funding of an affiliated trust — low standalone signal. $JEF · Jefferies Financial (investment bank): Sumitomo Mitsui Financial Group (10%+ owner) bought $318.7M. Why: SMBC is lifting its economic stake toward 20% under the global strategic alliance (Japan equities JV launches Jan 2027) — strategic accumulation, not an opportunistic trade · news. $STDN · Standard Nuclear (HALEU nuclear-fuel developer): Decisive Point Group (10%-owner) bought $19.1M. Why: large sponsor add in a pre-commercial fuel name levered to HALEU demand; main risk is pre-revenue execution. $ENR · Energizer Holdings (batteries / auto care): Aqua Capital (10%-owner) bought $1.66M. Why: 10% holder adding to a cheap, highly-levered consumer-staples turnaround. $LILA · Liberty Latin America (LatAm telecom): CEO/Chairman Michael Fries bought $1.0M. Why: classic top-insider conviction buy in a beaten-down name. $TYG · Tortoise Energy Infrastructure (energy closed-end fund): Prudential Financial (10%-owner) bought $60M. Why: fund-level structural position — limited directional signal. AXIA Energia (Brazil power, B3-listed): director Pedro Batista de Lima Filho bought $1.9M. Why: foreign-listed insider add — limited US relevance. 📊 Rest: +1 other 13D filing today (SPAC-sponsor filing — Columbus Circle Capital Corp III). Research only — not investment advice.

🗓 Activist & Insider Signals — Jul 16, 2026 🔍 EMERGING (high-conviction, not on roster) $AFB · AllianceBernstein National Municipal Income Fund (muni-bond closed-end fund) — 12.56% [High] Karpus Management (closed-end-fund discount activist, ~$4B AUM) Why: Karpus stepped up from passive holder to a 13D on a NAV-discounted muni CEF — its playbook is pressing the board for a tender, buyback or open-ending to close the discount. Catalyst: discount narrowing; risk: long-duration muni rate sensitivity. $CMMB · Chemomab Therapeutics (clinical-stage fibrosis/autoimmune biotech) — 12.5% [Med] HBM Healthcare Investments (Swiss-listed healthcare crossover fund, ~$1.5B portfolio) Why: HBM turned its 2024 PIPE into a 12.5% 13D — a specialist backing lead anti-fibrotic nebokitug ahead of PSC catalysts. Risk: binary clinical data & micro-cap liquidity. · news 💰 INSIDER BUYS Diameter Dynamic Credit Fund (new interval fund from $25B credit shop Diameter Capital): co-founder/CIO Scott Goodwin bought $1.25M. Why: manager seeding its just-launched vehicle — strong insider alignment, but not a tradable public equity. $ARDC · Ares Dynamic Credit Allocation Fund (Ares-run credit CEF): Thrivent Financial (10%-owner) bought $4.0M. Why: the buy was Mandatory Redeemable Preferred (Series D, $25 par) — a structural income allocation, NOT a bullish common-equity signal. · news $CRDF · Cardiff Oncology (clinical-stage colorectal-cancer biotech): Gary Pace (director) bought $1.0M. Why: sizable open-market director buy in a micro-cap oncology name; conviction ahead of onvansertib data. Risk: binary trial outcome. $VANI · Vivani Medical (GLP-1 drug-implant developer): Gregg Williams (director & 10%-owner) bought $1.0M. Why: chairman/large holder adding to a GLP-1 implant play on the obesity-drug theme. Risk: early-stage, pre-revenue. 📊 Rest: +4 other 13D filings today — control-type stakes (Trafalgar / Greater Cannabis 100%, Guo Li / AIOS Tech 60.6%, Scott Beck / Gloo Holdings 49%, Kenneth Lehman / BayFirst Financial 42.4%). Research only — not investment advice.

🗓 Activist & Insider Signals — Jul 17, 2026 (filings 07/15) 🔍 EMERGING (high-conviction, not on roster) $VVOS · Vivos Therapeutics, Inc. (sleep-apnea oral-airway medical devices) — 19.9% [Med] V-Co Investors 4 LLC (private investor group tied to Michael Skaff / SP Manager) Why: Skaff-affiliated V-Co vehicles built a 19.9% stake, mostly via a March-2026 private placement plus warrants, and filed a 13D reserving the right to engage on strategy/governance — a potential turnaround/engagement play on a micro-cap; main risk is warrant dilution and going-concern funding needs. · news 💰 INSIDER BUYS $BOT · RoboStrategy, Inc. (closed-end fund holding pre-IPO/public robotics): Andrew Kang (President/CEO, 10%+ owner) bought $10.0M. Why: the CEO put $10M in at NAV into his own "MicroStrategy of robotics" fund (holdings include Figure AI, Apptronik) — a strong conviction signal on pre-IPO robotics exposure; risk is the fund trades on hard-to-mark private NAV. · news $ENR · Energizer Holdings, Inc. (batteries & auto-care products): Aqua Capital, Ltd. (10% owner) bought $2.02M. Why: the 10%-owner group has been adding repeatedly in the open market through July near multi-year lows — sustained insider/value accumulation; risk is Energizer's high leverage and soft consumer demand. · news $FULC · Fulcrum Therapeutics, Inc. (clinical-stage genetic-disease biotech): Kevin Tang (10% owner) bought $891K. Why: Tang Capital added near the 52-week low (~$3.56, down ~66% over 6mo) — classic Tang deep-value biotech accumulation; watch for a restructuring or cash-return catalyst, risk is pipeline/clinical failure. · news Research only — not investment advice.

📊 Activist & Insider Signals — 2026-07-14 filings 🔍 EMERGING (high-conviction, not on roster) $MFPVV · Midera Food Processing (food-processing & food-safety equipment maker) — 7.5% [High] Garden Investment Management (Ed Garden's post-Trian activist fund, Greenwich CT) Why: Ed Garden's new activist shop disclosed a 7.5% stake in the just-completed Middleby food-processing spin-off (independent since Jul 6), with founding partner Brian Jacoby already on the board — a classic post-spin value-creation play; main risk is a tiny, illiquid newly-listed stock. · news. Book: 2 pos, top-10 100%. 💰 INSIDER BUYS $NTSK · Netskope (cloud/SASE cybersecurity, recent IPO): Griffith (director) & ICONIQ Strategic Partners VIII (10% owner) bought ~$3.8M [CLUSTER of 2]. Why: ICONIQ, Netskope's biggest backer, is doubling down after a steep post-IPO selloff — 28% YoY revenue growth underpins the conviction; risk is lockup supply/valuation. · news $GLBS · Globus Maritime (dry-bulk shipping): Feidakis Georgios (director) bought ~$603k. Why: chairman-linked director adding to a deep-discount micro-cap dry-bulk name. $NMM · Navios Maritime Partners (diversified shipping): Frangou Angeliki (director/officer/10% owner) bought ~$252k. Why: CEO Frangou keeps accumulating units under a 10b5-1 plan — a steady insider-buying signal in a cheap shipping name. 📊 Rest: +2 other 13D filings today (Brown Brothers Harriman and AMG New York Holdings control filings on the newly-formed AMG BBH Asset-Backed Credit Fund — structural fund-sponsor filings, no tradable equity). Research only — not investment advice.

🎯 Activist & Insider Signal Digest — 13 Jul 2026 🔍 EMERGING (high-conviction 13D, not on roster) GNK · Genco Shipping & Trading (US dry-bulk shipping operator) — 14.4% [Med] Diana Shipping Inc. (rival dry-bulk owner, ~$0.7B mkt cap) Why: Diana is running a cash-and-stock takeover of Genco at $27.34/sh ($24.80 cash + 1 DSX share); the 13D/A tracks its 14.4% toehold as ~30% of the float has tendered — pure merger-arb / event-driven, main risk is Genco board resistance (it filed a PREC14A defense). · news TDIC · Dreamland Ltd (micro-cap consumer/leisure, recent IPO) — 23.81% [Med] Seto Wai Yue (founder & CEO) Why: the CEO also bought $2.4M in the open market the same week — founder accumulating a thinly-traded name just after listing; conviction signal, but illiquidity/float risk is high. 💰 INSIDER BUYS IPX · IperionX (US recycled-titanium metals, defense/aerospace supply chain): Todd Hannigan (Exec Chairman) bought $1.88M and Anastasios Arima (CEO) bought $497k [CLUSTER of 2]. Why: chairman + CEO buying together after a ~46% six-month drawdown — strong two-insider conviction in a domestic-titanium reshoring play; risk is the pre-scale capex/ramp. · news COE · 51Talk Online Education (online English tutoring, China/Philippines): Jack Jiajia Huang (CEO) bought $9.31M. Why: CEO relentlessly accumulating via HH Talent under a 10b5-1 plan straight through a ~$28→$16 ADS slide — deep founder conviction. · news GLOO · Gloo Holdings (faith/community tech SaaS platform): Grace & Mercy Foundation (10% owner) bought $3.0M. Why: anchor holder adding to a recently public name — insider/anchor conviction, thin-float risk. CCCTU · Columbus Circle Capital Corp III (SPAC): sponsor Columbus Circle 3 Sponsor Corp LLC (10% owner) bought $2.65M. Why: routine SPAC-sponsor at-risk capital — low standalone signal. TDIC · Dreamland Ltd (micro-cap consumer/leisure): Seto Wai Yue (CEO) bought $2.445M. Why: mirrors the CEO's 23.81% 13D above — founder doubling down post-IPO. GGAL · Grupo Financiero Galicia (Argentina's largest private-sector bank holding): Moret Silvestre Vila (director) bought $2.16M. Why: insider adding to an Argentina reform / macro-recovery proxy. ENR · Energizer Holdings (batteries + auto-care consumer staples): Aqua Capital, Ltd. (10% owner) bought $1.23M. Why: Aqua steadily accumulating (now ~7.5M sh) — value/turnaround add on weakness. · news

CAI · Caris Life Sciences (cancer molecular diagnostics/profiling): Jon Halbert (director) bought $990k [Med]. Why: director adding to a recent precision-oncology IPO. CMC · Commercial Metals (recycled steel & rebar): Peter R. Matt (President & CEO) bought $504k [Med]. Why: CEO open-market buy levered to US construction/infra demand. YEXT · Yext (digital knowledge / search-experience SaaS): Daniel J. Englander (director) bought $398k [Med]. PRQR · ProQR Therapeutics (RNA-editing / Axiomer platform, Netherlands): Daniel de Boer (CEO) bought $261k [Med]. Why: CEO buying a small-cap clinical-stage biotech at ~$1.74. Research only — not investment advice.

📡 Activist & Insider Signals — 10 Jul 2026 2 new Schedule 13Ds · 9 insider buys from 712 Form 4s scanned 🔍 EMERGING (high-conviction, not on roster) $CALC · CalciMedica (clinical-stage CRAC-channel biopharma, acute pancreatitis) — 17.1% [Med] Alafi Capital Co LLC (long-time biotech venture investor) Why: Founder-tied VC Christopher Alafi deepened to 17.1% via a late-June unit+warrant purchase on top of years of open-market buys — high insider conviction ahead of acute-pancreatitis readouts; risk is a clinical-stage binary and warrant dilution. · news $EVGN · Evogene (Israeli computational ag-biology & drug discovery) — 12.6% [Med] L.I.A. Pure Capital (activist investment firm, Kfir Silberman) Why: Pure Capital (12.6%), with Invest-Pro together at 16.7%, filed a 13D and demanded a special shareholder meeting — an active governance/board catalyst; risk is a cash-strapped micro-cap. 💰 INSIDER BUYS (clusters first) $NTSK · Netskope (cloud/SASE security, IPO’d 2025): ICONIQ Strategic Partners VIII / director William Griffith (10%-owner) bought ~$7.2M @ $11.82. Why: Netskope’s biggest backer added right after a steep selloff — long-term conviction from an insider fund. · news $GLOO · Gloo Holdings (values/faith-based tech platform): Scott Beck (CEO), Derek Green (director) & Pat Gelsinger (ex-Intel CEO, exec chair) bought ~$6.0M combined @ $3.25 [CLUSTER of 3]. Why: insiders backstopped the July 10 public offering — strong alignment on a capital-raising small-cap; risk is ongoing dilution. · news $AVO · Mission Produce (global avocado grower/distributor): Globalharvest Holdings (10%-owner) bought $7.9M @ $13.28. Why: strategic holder relentlessly accumulating on strength (now ~11.2M sh) — sustained conviction; risk is weather/commodity swings. · news $CV · CapsoVision (AI capsule-endoscopy medical devices): Eliyahou Harari (10%-owner, SanDisk founder) bought $0.50M @ $6.09. Why: founder-level insider adding above the $5 IPO price a year post-listing — modest but a conviction tell. 📊 Also: 2 insider filings excluded as data-flagged (implausibly reported price/value). Research only — not investment advice.

📊 Activist & Insider Signals — Jul 9, 2026 13D accumulation + qualifying insider buys, ranked by conviction 🔍 EMERGING (high-conviction, not on roster) $YEXT · Yext, Inc. (digital presence & listings SaaS) — 19.0% [High] Lynrock Lake LP (concentrated equity hedge fund, ~$2.6B AUM) Why: Flipped its passive holding to an active 13D as founder Cynthia Paul joined Yext's board (Jul 7) — now the largest holder at 19%, signaling a push on strategy/capital return. Risk: sluggish SaaS growth. · news. Book: 23 pos, top-10 95.2% $SITM · SiTime Corp (precision MEMS timing chips) — 11.9% [High] Renesas Electronics America (Japanese semiconductor maker, strategic holder) Why: Stake came from selling its timing business to SiTime (closed Jul 1, ~$1.5B cash + stock) plus a board seat — a strategic lock-up, not activism; near-term selling constrained. Catalyst: combined timing franchise for AI/datacenter. Risk: eventual Renesas share overhang. · news. Book: 1 pos, top-10 100.0% $HQWWW · Horizon Quantum Holdings (quantum-computing software, deSPAC'd Mar 2026) — 20.3% [Med] Peak XV Partners (ex-Sequoia India/SEA VC, ~$9B AUM) Why: Pre-IPO backer keeping a large stake post-deSPAC — long-horizon conviction on quantum software; highly speculative, pre-revenue with cash burn. · news

$BENFW · Beneficient (liquidity/fintech for illiquid alt-assets) — 7.5% [Med] James G. Silk (individual insider/affiliate) Why: Insider disclosing a 7.5% 13D in a distressed micro-cap — worth watching but high risk: going-concern and dilution overhang. $SECZ · Securitize Corp. (RWA tokenization platform, NYSE debut Jul 2) — 6.0% [Med] William Bradford Stephens (insider/affiliate) Why: Post-deSPAC insider ownership disclosure (>5%) in a BlackRock-backed tokenization name — structural holding, not fresh buying. Risk: lock-ups/redemptions, crypto-regulatory. · news $SECZ · Securitize Corp. (RWA tokenization platform, NYSE debut Jul 2) — 5.4% [Med] Carlos Francisco Domingo Soriano (co-founder/CEO) Why: Founder-CEO 5.4% insider stake disclosed alongside the listing — insider alignment; same lock-up/crypto-reg risks as above.

💰 INSIDER BUYS $EWSB · EWSB Bancorp (Maryland community bank, recent thrift-conversion IPO): Charles Schmalz (CEO/director) bought $676K, Kory Schneider (officer) $479K, James Mangold (officer) $400K [CLUSTER of 3]. Why: Classic post-IPO insider cluster near IPO price — confidence + tangible-book value play. $AVO · Mission Produce (avocado grower & distributor): Globalharvest Holdings (10%-owner) bought ~$15.8M. Why: Largest holder aggressively adding at ~$12–13 — strong conviction on avocado pricing/volume recovery. · news $GGAL · Grupo Financiero Galicia (Argentina's largest private bank, ADR): Silvestre Vila Moret (director) bought $2.1M. Why: Insider conviction on Argentine macro recovery/rate cuts under Milei reforms. Risk: peso & political volatility. $ENR · Energizer Holdings (batteries & auto-care): Aqua Capital (10%-owner) bought ~$1.6M — 13 buys / 0 sells over the past year. Why: Relentless value accumulation by the top holder in a deleveraging consumer-staples turnaround. $UUUU · Energy Fuels (US uranium & rare-earths producer): Ross Bhappu (officer) bought $968K. Why: Management buying into the uranium/rare-earths upcycle. Also flagged (structural, not conviction): sponsor NAV contributions into interval credit funds — BBASX (AMG BBH Asset-Backed Credit) ~$2.3M and CCLFX (Cliffwater Corporate Lending) $415K. Research only — not investment advice.

🗓 Activist & Insider Signals — July 8, 2026 🔍 EMERGING (high-conviction, not on roster) $GNK · Genco Shipping (US-listed dry-bulk shipping owner) — 14.4% [Med] Diana Shipping (NYSE dry-bulk shipping company, Genco's largest holder) Why: Live takeover — Diana's sweetened tender (~$27.34/sh: $24.80 cash + 0.1 Diana share) expires July 10, so a 13D/A here is textbook merger-arb. Risk: bid fails if too few shares tender. · news $MOVE · Corvex (newly-public AI-cloud / GPU-infrastructure firm) — 20.0% + 14.8% [Med] Seth Demsey & Jay Crystal (co-founders / co-CEOs) — filed SCHEDULE 13D Why: Founder control stakes reported after Corvex's March de-SPAC with Movano — concentrated insider ownership in a hot AI-infra name, not outside accumulation. Risk: thin post-merger float, unproven revenue. · news $GRDX · GridAI Technologies (micro-cap grid-software & GI-biopharma) — 7.1% [Med] Jason David Sawyer (individual filer) — filed SCHEDULE 13D Why: New 7.1% stake in a loss-making micro-cap (TTM −$18M) facing a Nasdaq late-filing delisting clock (extension to Oct 2026). Speculative; high delisting/dilution risk.

💰 INSIDER BUYS $EWSB · EWSB Bancorp (newly-converted Maryland savings-bank holding co.): Charles D. Schmalz (CEO/dir) $676k, Kory J. Schneider (officer) $479k & James E. Mangold (officer) $399k — all at the $10 IPO price [CLUSTER of 3]. Why: Textbook thrift-conversion insider buying at the subscription price; management backing a freshly-raised, over-capitalized balance sheet. · news $COE · 51Talk Online Education (China-based online English tutoring): Jack Jiajia Huang (CEO, dir/10% owner) bought ~$23.5M via HH Talent. Why: CEO's largest cluster yet in a months-long 10b5-1 buying campaign — strong conviction, though purchases are pre-scheduled. · news $AVO · Mission Produce (global avocado grower/distributor): Globalharvest Holdings (10% owner) bought ~$8.3M. Why: Largest outside holder adding aggressively right after AVO's $430M deal to buy rival Calavo — event-driven vote of confidence. Risk: integration/antitrust. · news $VII · Viking Acquisition Corp. II (blank-check SPAC): Hakan Wohlin (dir/officer/10%) bought $3.0M. Why: SPAC sponsor/insider funding — routine pre-deal capital, low standalone signal until a target is named. $MERC · Mercer International (pulp & solid-wood producer): Peter R. Kellogg (10% owner) bought ~$363k. Why: Long-time major holder adding on weakness in a cyclical pulp name. 📊 Rest: no additional 13D filings beyond those above (5 rows scanned, 4 unique). Research only — not investment advice.

🗓️ Alpha Digest — 29 Jun 2026 🎯 PRIORITY (roster names) $ALKT · Alkami Technology (cloud digital-banking platform for banks & credit unions) — 6.3% [High] · roster: Barry Rosenstein / JANA Partners JANA Partners (activist hedge fund, ~$1.5B AUM) — filed SCHEDULE 13D · 13FScore 49/100 Why: JANA is pushing Alkami to explore a sale and is engaging multiple potential acquirers, plus board/governance change — an event-driven M&A catalyst; main risk is no deal materializing and the stock giving back gains. · news. Book: 10 pos, top-10 100%. 🔍 EMERGING (high-conviction, not on roster) $KARD · Kardigan (late-stage cardiovascular drug developer) — 16.2% [Med] ARCH Venture Partners (leading biotech venture firm, ~$12B AUM) Why: ARCH was a lead pre-IPO backer holding through Kardigan’s 18 Jun IPO ($16/sh, ~$400M raised) — pre-IPO conviction continuing post-IPO behind the ex-MyoKardia team ($13B exit); risk is binary Phase 2b/3 readouts. · news $GNK · Genco Shipping & Trading (dry-bulk shipping) — 14.4% [Med] Diana Shipping (dry-bulk shipowner, Genco’s largest holder) Why: Diana (with Star Bulk) is running a tender offer at ~$27.34/share (~53% premium), extended to 10 Jul — active event-driven M&A; risk is Genco board resistance and the deal breaking. · news $MANU · Manchester United (English football club) — 54.5% [Med] INEOS (chemicals & sports group, Jim Ratcliffe) Why: a control/consolidation 13D from Ratcliffe’s INEOS rather than a trading catalyst; limited near-term float impact. $CRGOW · Freightos (freight-booking & rate-data platform) — 6.1% [Med] Zvi Schreiber (Freightos founder, ex-CEO turned activist) Why: the founder, who stepped down in early 2026, is re-engaging via a 13D pushing board change and a return to a high-growth strategy; risk is a protracted governance fight in a micro-cap. · news 💰 INSIDER BUYS $MOBI · Mobia Medical (medical-device maker): Green Park & Golf Ventures (10%-owner) bought $2.6M [CLUSTER of 2]. Why: the Texas healthcare VC’s two related entities bought at the $15 IPO price post-listing — lead pre-IPO backer doubling down; risk is a thin micro-cap float.

$JEF · Jefferies Financial (investment bank): Sumitomo Mitsui Financial (strategic holder) bought $352.5M. Why: SMBC is lifting its economic stake toward ~20% via open-market commons (later converted to nonvoting) — a deepening alliance and large supportive buyer, though nonvoting. · news $CGON · CG Oncology (bladder-cancer biotech): director Brian Liu bought $24.8M. Why: a large open-market director buy (via Seven Fleet) signals conviction alongside a follow-on raise; risk is clinical/commercial execution. · news $NXST · Nexstar Media (TV-broadcast group): CEO Perry Sook bought $2.0M. Why: a classic CEO open-market vote of confidence amid broadcast-M&A consolidation; risk is the ad cycle and regulatory review. · news $PBLS · Parabilis Medicines (oncology biotech): 10%-owner Guy Levy bought $10.0M. $HMMR · Hammer Technology Holdings (tech holding co): CEO Michael Cothill bought $2.7M. Smaller biotech-crossover adds: RA Capital → $ARTV Artiva ($0.3M), Kevin Tang → $BOLD Boundless Bio ($0.7M), Opaleye → $ACOG Alpha Cognition ($1.0M); plus Marcos Mindlin → $PAM Pampa Energía ($1.0M). 📊 Scanned: 5 activist 13D/13D-A filings (all shown above) + 14 passive 13G filings; 61 insider Form 4 buy-lines (13 unique issuers). Research only — not investment advice.

📊 Activist & Insider Signal Digest — 26 Jun 2026 🔍 EMERGING (high-conviction, not on roster) $BRCB · Black Rock Coffee Bar (drive-thru coffee chain, May-2026 IPO) — 52.6% [High] Cynosure Group (Salt Lake City family-backed PE, ~$5B AUM) — filed SCHEDULE 13D Why: Pre-IPO backer since 2020 bought out the founders’ margin-loan collateral ($72.9M) and locked in a board seat, deepening control of a fast-growing chain. Catalyst: sponsor conviction + store expansion; risk: 52.6% control caps float/minority say. · news $OPIRQ · Office Properties Income Trust (office REIT, just exited Ch.11) — 25.3% [High] Helix Partners Management (distressed-debt specialist, ~$1.8B AUM) Why: Converted OPI noteholdings into 25.3% equity as the REIT shed $714M of debt; founder Jon Heller now chairs the board — a creditor-turned-owner reorg play. Risk: still $1.7B debt and weak office demand. · news $OPIRQ · Office Properties Income Trust (office REIT, post-reorg equity) — 19.7% [High] Redwood Capital Management (Kolatch distressed-credit fund, ~$10B AUM) · 13FScore 59/100 Why: Took 19.7% via the same restructuring with rights to two trustees — betting on a deleveraged recovery. 13F clone slightly trails the S&P; risk: secular office decline. · news $JRVR · James River Group (specialty insurer) — 10.0% [High] Zimmer Partners (multi-strategy hedge fund, ~$5B AUM) · 13FScore 61/100 Why: Flipped from passive to an activist 13D at 10%, pushing to cut dividends, repay debt and explore a sale of the undervalued insurer. Catalyst: activist break-up/sale; risk: reserve adequacy. · news $ODTX · Odyssey Therapeutics (clinical-stage inflammation biotech) — 7.8% [High] TPG (global alternative-asset manager, ~$250B AUM) Why: TPG Life Sciences added $25M in a concurrent private placement at Odyssey’s May IPO — pre-IPO conviction continuing post-listing. Catalyst: Phase 2a RIPK2 (ulcerative colitis) data; risk: binary clinical/cash burn. · news

$GEMI · Gemini Space Station (newly-public crypto exchange) — 65.1% [Med] Winklevoss Capital Fund (the twins’ family fund) Why: Injected $100M paid in ~1,258 BTC and shifted to an active 13D at 65.1% — founders doubling down on their own exchange. Catalyst: crypto-cycle leverage + founder control; risk: regulatory/crypto volatility, tiny float. · news $LFWD · Lifeward (Nasdaq medical-device maker) — 49.9% [Med] Oramed Pharmaceuticals (clinical-stage pharma, strategic investor) Why: Took ~49.9% via convertible notes + warrants while transferring its POD oral-drug tech — effectively reverse-merging its pipeline into a listed shell. Catalyst: strategic recapitalization; risk: note/warrant dilution, execution. · news 📊 Rest: +91 other 13D filings today (low conviction / small stakes / control & SPAC-sponsor filings, incl. StepStone & Franklin fund-control 13Ds). Research only — not investment advice.